Skip to main content

Driving Better Healthcare Decisions

An AI data science and translational research company.
Trusted. Transparent. Traceable.

Talk to our team

What we do

Reverse engineering clinical insights from real world EMR data to identify evidence that drive future research and innovation.

Medical knowledge is too vast and scattered for any one person to synthesize. We bring it together to reconstruct patient journeys at a speed and scale people can't match.

From record to evidence

Raw records become research-ready evidence.

One pipeline, five steps. Follow a single clinical note all the way to cohort-level analysis.

  1. The source

    It starts with a clinical note.

    Unstructured notes hold most of the clinical story.

    progress_note.txt

    Patient: [de-identified] Visit: 14 Mar 2023

    CHIEF COMPLAINT

    Follow-up of type 2 diabetes, diagnosed 2019, and hypertension.

    HISTORY OF PRESENT ILLNESS

    Reports fatigue over the past month and mild GI upset since starting empagliflozin 10 mg in January.

    MEDICATIONS

    Metformin 1000 mg BID since 2019. Lisinopril 20 mg daily since 2020. Atorvastatin 40 mg nightly since 2021.

    RESULTS

    A1c 7.4%, down from 7.9% in November. LDL 88 mg/dL. BP 128/78.

    ASSESSMENT & PLAN

    Diabetes improving on current regimen. Continue metformin and empagliflozin. Recheck A1c in three months.

    Source document · de-identified

  2. Extraction

    Clinical notes become atomic facts.

    Each fact is tagged by category and date.

    progress_note.txt

    Patient: [de-identified] Visit: 14 Mar 2023

    CHIEF COMPLAINT

    Follow-up of type 2 diabetes, diagnosed 2019, and hypertension.

    HISTORY OF PRESENT ILLNESS

    Reports fatigue over the past month and mild GI upset since starting empagliflozin 10 mg in January.

    MEDICATIONS

    Metformin 1000 mg BID since 2019. Lisinopril 20 mg daily since 2020. Atorvastatin 40 mg nightly since 2021.

    RESULTS

    A1c 7.4%, down from 7.9% in November. LDL 88 mg/dL. BP 128/78.

    ASSESSMENT & PLAN

    Diabetes improving on current regimen. Continue metformin and empagliflozin. Recheck A1c in three months.

    Source document · de-identified
    • Type 2 diabetes2019
    • Hypertension2020
    • FatigueFeb 2023
    • GI upsetJan 2023
    • Empagliflozin 10 mgJan 2023
    • Metformin 1000 mg2019
    • Lisinopril 20 mg2020
    • Atorvastatin 40 mg2021
    • A1c 7.4%Mar 2023
    • A1c 7.9%Nov 2022
    • LDL 88 mg/dLMar 2023

  3. One patient

    Each fact aligns to the patient’s timeline.

    A complete longitudinal medical history.

    See a full journey
    Timeline of one patient’s records across four clinical domains, 2017 to 2025VISITSDiagnosesMedicationsLabsSymptomsMetforminLisinoprilAtorvastatinEmpagliflozin201720182019202020212022202320242025

  4. Every patient

    Patient journeys, stacked.

    Every patient has their own sequence of events. Together they become a cohort.

  5. Analysis

    Research-ready longitudinal evidence.

    Cohorts compared over observed time, ready for review.

    Proportion remaining on first-line therapy

    Step chart comparing two cohorts on the proportion remaining on first-line therapy over 36 months, with Cohort A ending 11 points higher1.00.90.80.70.60.5061218243036Months from therapy startCohort ACohort B+11 pts at 24 months

    Illustrative data

At scale

Real-world depth, not just volume.

Longitudinal records that carry scientific weight, with the unstructured layer that other tools cannot read.

2B+
Patient records in the data lake
40,000+
Provider sites covered
35M+
Patients used to train and validate the platform's models
~80%
Of clinical knowledge lives in unstructured notes
36
EHRs integrated
Explore the data foundation
How we build

Trusted. Transparent. Traceable.

Three commitments sit underneath everything the platform does, by design and from the start.

Trusted

Every output is anchored in source data and validated steps, not model intuition.

Transparent

Users see the code, the intermediate tables, and the path from raw note to final result.

Traceable

Every claim links back to its source span in the original record.

What makes us different?

Analysis-ready data at scale.
Your Knowledge Galaxy™.
  • Multidimensional data.
  • The full patient journey.
  • Grounded in medical knowledge.
Built for your research workflow.
Your clinical research agent.
  • Decides what tool to use for your question.
  • Works inside your existing workflow.
  • You stay in the loop.
State of the art accuracy.
Trustable, traceable, transparent.
  • No black box.
  • Always reviewable & reproducible.
  • Every claim is source-linked.
Learn more
Who it's for

Insights for clinical researchers at speed and scale.

Pharmaceutical & Biotech

Label expansion, post-market surveillance, treatment-response subgroup analyses, comparative effectiveness, and rare-disease characterization.

Point-of-Care

Surface clinical complexity hidden in narrative notes. Improve revenue capture and care management without adding physician burden.

DiabetesA1cHypertensionGLP-1 agonistMetforminCKD stage 3ASCVD riskCONTEXTPATIENT HISTORY

The Next Frontier: Predictive Insights

Our Foundational Patient Model predicts the journey and the route ahead

Context

The map is medical knowledge

Our proprietary patient data embedded with ontologies & regulatory labels, and informed by published literature and domain expertise.

Observed

Observed the patient journey to date

A Knowledge Galaxy of where patients have been and are currently, drawn from longitudinal records.

Expected

Expected is the route ahead

The foundational model generates probabilities of where patients are heading.

Talk to our team.

Whether you are scoping a study, building an evidence package, or evaluating a platform, we would like to understand your question.

Get in touch